Pharvaris NV (NASDAQ: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema, on Tuesday announced positive top-line results from its CHAPTER-3 pivotal Phase 3 study of deucrictibant extended-release (XR) for preventing hereditary angioedema (HAE) attacks.
The company plans to use the data to support marketing authorisation applications from the first half of 2027.
The global, double-blind, placebo-controlled study enrolled 85 participants across 21 countries and evaluated once-daily deucrictibant XR for 24 weeks. Participants receiving deucrictibant XR recorded an 83% reduction in mean monthly attack rate versus placebo (p
Genezen agrees manufacturing collaboration with Galibra Neuroscience
Viking Therapeutics launches Phase 3 clinical programme for oral VK2735 in obesity
Coya Therapeutics plans open-label extension of COYA 302 ALS trial
Takeda reports positive Phase 2/3 results for investigational immunodeficiency therapy
Galderma to acquire ZO Skin Health for USD1.5bn to expand skincare portfolio
Orexo reports encouraging initial bioavailability results for oral semaglutide formulation
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Telix to present 20 abstracts on cancer theranostics at EANM Congress
CelLBxHealth secures USD65,000 pharmaceutical research contract
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
ArkBio reports FDA clearance of IND application for AK0406
Enodia Therapeutics partners with Pfizer on Sec61-targeting drug development